Creative Medical Technology Holdings Inc (NASDAQ: CELZ) Announces That StemSpine has High Efficacy

Creative Medical Technology Holdings Inc (NASDAQ: CELZ) has announced that its therapy StemSpine has high efficacy. The company developed the drug to treat chronic pain in the lower back. It announced the effectiveness of the treatment following data from a follow-up two years after its pilot study. Fortunately, the procedure didn’t produce any significant side effects.

StemSpine is a procedure the company came up with to treat back pain. The process works by using bone marrow from the patient to treat their lower back pain. Researchers concluded that it had an 87% efficacy rate. Moreover, the volunteers didn’t report any severe complications

The company has stated it is happy to have its data in a peer-reviewed journal. It also plans to discuss its findings at several orthopedic events in the future.

The company is working on commercializing the procedure

According to the company CEO and President, Timothy Warbington, the company is excited to report the results of its two-year trial. Seeing that the process was a success, Creative Medical Technology is now working towards introducing it to practitioners and commercializing it.

How the therapy worked

Warbington explains that the procedure involved the researchers removing bone marrow from the patient’s spine and injecting it into areas around the disc. This move repaired, remodeled, and improved blood supply in the lower back and near the discs. The team thinks that the treatment could be a good option for patients with severe pain in the lower back who can’t get surgery.

The company’s Chief Commercialization Officer, Sahil Nock, adds that the good news has come soon enough for the annual American Academy of Orthopaedic Surgeons Conference, Chicago.

The conference will take place between March 22 and March 26. Nick explains that the findings could be significant to the orthopedic surgeons present for the meeting.

The company is a biotechnology company that focuses on stem cell therapies. It works toward producing therapies in several areas, including orthopedics, neurology, urology, and immunotherapy.

The company also uses its subsidiary, Creative Medical Technologies Inc, to commercialize its therapies. This subsidiary already sells FemCelz and CaverStem. These therapies are for female sexual dysfunction and erectile dysfunction, respectively.